AstraZeneca: Pipeline, Products, Performance, Potential

Table of Contents

• Principal Operating Results
• Latest Results

EXECUTIVE SUMMARY

• Introduction
  • Current Growth Drivers
  • Key Late-Stage Products
  • Key Early-Stage Products
• Financial Performance 2005
  • Sales and Market Position
  • Income
    • Sales, Costs and Operating Income
  • Expenditure
    • Capital Expenditure
    • R&D Expenditure
  • Divisional Performance
  • Geographic Performance
    • During 2005:
    • Sales By Destination
    • Sales By Origin
    • Operating Income By Geographic Segment
    • Total Assets By Geogrpahic Area
• Company Strategy
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
  • Production
  • Employees
    • Employees By Geographic Area (Average)
• Product / R&D Overview
  • Key Products
    • Recent Product Launches
    • Recent Product Approvals
    • Discontinued Products
  • R&D Strategy
    • Discovery
    • Development
    • Key R&D Projects
  • R&D Pipeline Overview
    • Discontinued R&D projects
  • Sales Forecast
• Conclusions

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

• Major Products, Therapeutic Areas and Sales
• R&D Pipeline
• Gastrointestinal - Products
  • Sales
  • Major Launched Products
  • Nexium
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Patents
    • Generic Competition/Lawsuits
    • Sales Forecast
    • Clinical Trial Results - NSAID GI Side Effects
    • Clinical Trial Results - ZES and Idiopathic Gastric
    • Hypersecretion
    • Clincial Trial Results - Asthma
    • Clinical Trial Results - Non-GORD Dyspepsia
    • Clinical Trial Results - Coronary Artery Disease
  • Others
• Gastrointestinal - R&D
  • AZD3355
  • AZD9056
  • AZD9272
• Gastrointestinal - Summary
  • Growth Potential
  • Limiting Factors
• Cardiovascular - Products
  • Sales
  • Major Launched Products
  • Atacand
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Patents
    • Sales Forecast
    • Clinical Trial Results - Diabetic Retinopathy
  • Crestor
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Safety Issues
    • Competitor Products
    • Generic Competition
    • Sales Forecast
    • Clincial Trial Results - Comparative Studies
    • Clinical Trial Results - Regression Of Atherosclerosis
    • Clinical Trial Results - Renal Outcomes
  • Seloken/Toprol
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Patents
    • Generic Competition/Lawsuits
    • Sales Forecast
  • Others
• Cardiovascular - R&D
  • AGI-1067
  • AZD0837
  • AZD2479
  • AZD6140
    • Clinical Trial Results - Acute Coronary Syndrome
  • AZD6610
  • AZD7009
    • Clinical Trial Results - AF
  • AZD8677
  • AZD9684
• Cardiovascular - Summary
  • Growth Potential
  • Limiting Factors
• Neuroscience - Products
  • Sales
  • Major Launched Products
  • Seroquel
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Safety Issues
    • Competitor Products
    • Patents
    • Generic Competition
    • Lawsuits
    • Sales Forecast
    • Clinical Trial Results - Major Depressive Episodes In BPD
    • Clinical Trial Results - Depression
    • Clinical Trial Results - Aggressive Behaviour In Schizophreniarelated
    • Psychotic Episodes
  • Others
• Neuroscience - R&D
  • AZD1080
  • AZD2327
  • AZD3480
  • AZD5904
  • AZD9272
  • NXY-059
    • Clinical Trial Results - Acute Ischaemic Stroke
    • Clinical Trial Results - Acute Intracerebral Haemorrhage
  • TC-1734
• Neuroscience - Summary
  • Growth Potential
  • Limiting Factors
• Cancer- Products
  • Sales
  • Major Launched Products
  • Arimidex
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Patents/Licensees
    • Sales Forecast
    • Clinical Trial Results - ATAC
    • Clinical Trial Results - Combination with Herceptin
  • Casodex
    • Sales
    • Key Markets/Indications/Formulations
    • Competitor Products
    • Patents/Licensees
    • Generic Competition
    • Sales Forecast
    • Clinical Trial Results - Prostate Cancer
  • Faslodex
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Clinical Trial Results - Breast Cancer
  • Iressa
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Clinical Trial Results - ISEL
    • Clincial Trial Results - Breast Cancer
  • Zoladex
    • Sales
    • Key Markets/Indications/Formulations
    • Competitor Products
    • Patents
    • Lawsuits
    • Sales Forecast
  • Others
• Cancer - R&D
  • AZD0530
  • AZD1152
  • AZD1689
  • AZD2171
  • AZD2281
  • AZD4769
  • AZD5896
  • AZD6244
  • CAT-5001
  • Zactima
    • Clinical Trial Results - NSCLC
    • Clinical Trial Results - Thyroid Cancer
  • ZD4054
• Cancer - Summary
  • Growth Potential
  • Limiting Factors
• Respiratory and Inflammation - Products
  • Sales
  • Major Launched Products
  • Pulmicort
    • Sales
    • Key Markets/Indications/Formulations
    • Safety Issues
    • Competitor Products
    • Patents
    • Lawsuits
    • Sales Forecast
  • Symbicort
    • Sales
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Patents
    • Sales Forecast
  • Others
• Respiratory and Inflammation - R&D
  • AZD1981
  • AZD3342
  • AZD5672
  • AZD5904
  • AZD8309
  • AZD8955
  • AZD9056
• Respiratory and Inflammation - Summary
  • Growth Potential
  • Limiting Factors
• Infection - Products
  • Sales
  • Major Launched Products
  • Merrem
    • Sales
    • Key Markets/Indications/Formulations
    • Competitor Products
    • Generic Competition
    • Sales Forecast
  • Others
• Infection - R&D
  • CytoFab
    • Clinical Trial Results - Severe Sepsis
• Infection - Summary
  • Growth Potential
  • Limiting Factors

APPENDIX 1 - FINANCIAL PERFORMANCE

• Full Year Results 2005

APPENDIX 2 - KEY AGREEMENTS

• Abbott
  • 5th July 2006
• Abgenix Inc
  • 29th October 2003
• Abraxis BioScience Inc
  • 27th April 2006
  • 28th June 2006
• Array BioPharma Inc
  • 18th December 2003
  • June 2004
  • 24th January 2006
  • 10th April 2006
  • 8th June 2006
  • 14th September 2006
• Astex Therapeutics Ltd
  • 3rd May 2001
  • 25th March 2002
  • 3rd March 2003
  • 7th July 2003
  • 19th April 2004
  • 27th July 2005
• AtheroGenics
  • On 22nd December 2005
  • 30th January 2006
• Avanir Pharmaceuticals
  • 11th July 2005
  • 3rd January 2006
• Biovail Pharmaceuticals
  • 2nd May 2005
• Cambridge Antibody Technology (CAT)
  • 22nd November 2004
• Caprion Pharmaceuticals
  • 1st November 2005
• Dainippon Sumitomo Pharma
  • 31st May 2000
  • 1st October 2000
  • 15th January 2004
• Dyax Corp
  • 14th May 2002
• Dynavax Technologies
  • 6th September 2006
• Eisai
  • 30th July 2004
• Eli Lilly
  • 20th December 2001
• Enzon Pharmaceuticals
  • 27th July 2006
• Epigenomics AG
  • 16th May 2006
• Inyx Inc
  • 29th June 2004
• NPS Pharmaceuticals Inc
  • 28th March 2001
  • 8th February 2006
• Pozen
  • 2nd August 2006
  • 21st September 2006
• Procter & Gamble
  • 15th December 1997
  • 15th September 2003
  • 18th November 2004
• Prometheus Laboratories Inc
  • 1st December 2004
  • 11th January 2005
• Protherics
  • 8th December 2005
  • 12th January 2006
• sanofi-aventis
  • 17th June 2002
• Schering AG
  • 27th July 2005
• Scil Proteins
  • 19th July 2006
• SkyePharma PLC
  • 7th January 2002
  • 28th June 2005
• Targacept
  • 28th December 2005
  • 6th February 2006
• The Medicines Company (TMC)
  • 6th March 2002
  • 19th May 2003
  • 18th December 2003
• ViroLogic Inc
  • 7th March 2005

APPENDIX 3 - INFRASTRUCTURE

• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 4 - KEY PHARMACEUTICAL

• SUBSIDIARIES / JOINT VENTURES
• Subsidiaries
• Joint Ventures

APPENDIX 5 - PRODUCT INDEX

Index of Tables

• Principal Operating Results
• Sales, Costs and Operating Income
• Sales By Destination
• Sales By Origin
• Operating Income By Geographic Segment
• Total Assets By Geogrpahic Area
• Employees By Geographic Area (Average)
• Recent Product Launches
• Recent Product Approvals
• Key R&D Projects
• Major Products, Therapeutic Areas and Sales
• R&D Pipeline
• Major Launched Products
• Major Launched Products
• Major Launched Products
• Major Launched Products
• Major Launched Products
• Major Launched Products

Index of Charts

• R&D Expenditure and Capital Expenditure
• Sales By Destination, 2005
• Sales By Origin
• Operating Income By Geographic Segment, 2005
• Total Assets By Geographic Area, 2005
• Employess By Geographic Area, 2005
• Forecast Sales of Major Products (2000A-2010E)
• Sales of Top Ten Products, 2005
• Nexium Sales (2000A-2010E)
• Crestor Sales (2000A-2010E)
• Seloken Sales (2000A-2010E)
• Seroquel Sales (2000A-2010E)
• Arimidex Sales (2000A-2010E)
• Casodex Sales (2000A-2010E)
• Zoladex Sales (2000A-2010E)
• Pulmicort Sales (2000A-2010E)
• Symbicort Sales (2000A-2010E)
• Merrem Sales (2000A-2010E)
• Sales, Costs and Operating Income
• Profitability and Research Ratios
• R&D Expenditure and Capital Expenditure
• Current Assets, Liabilities and Ratio
• Assets, Cash and Liquidity
• Employees and Productivity